Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response
Conclusions: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy. (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Source Type: research

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis
This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute. Results: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI], 1.23 –7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI, 1.58–5.53; p (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Source Type: research

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response
CONCLUSIONS: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy.PMID:35016175 | DOI:10.1159/000521912 (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Daehun Kwag Jae-Ho Yoon Gi June Min Sung-Soo Park Silvia Park Sung Eun Lee Byung-Sin Cho Ki-Seong Eom Yoo-Jin Kim Hee-Je Kim Seok Lee Chang-Ki Min Seok-Goo Cho Jong Wook Lee Source Type: research

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis
This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute.RESULTS: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI], 1.23-7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI, 1.58-5.53; p
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Yosuke Okada Masahiro Teramoto Noriaki Tachi Toshikuni Kawamura Toshikatsu Horiuchi Shoichiro Kato Takaaki Maekawa Yukiko Osawa Shinichi Kobayashi Fumihiko Kimura Source Type: research

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response
CONCLUSIONS: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy.PMID:35016175 | DOI:10.1159/000521912 (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Daehun Kwag Jae-Ho Yoon Gi June Min Sung-Soo Park Silvia Park Sung Eun Lee Byung-Sin Cho Ki-Seong Eom Yoo-Jin Kim Hee-Je Kim Seok Lee Chang-Ki Min Seok-Goo Cho Jong Wook Lee Source Type: research

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis
This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute.RESULTS: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI], 1.23-7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI, 1.58-5.53; p
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Yosuke Okada Masahiro Teramoto Noriaki Tachi Toshikuni Kawamura Toshikatsu Horiuchi Shoichiro Kato Takaaki Maekawa Yukiko Osawa Shinichi Kobayashi Fumihiko Kimura Source Type: research

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response
CONCLUSIONS: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy.PMID:35016175 | DOI:10.1159/000521912 (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Daehun Kwag Jae-Ho Yoon Gi June Min Sung-Soo Park Silvia Park Sung Eun Lee Byung-Sin Cho Ki-Seong Eom Yoo-Jin Kim Hee-Je Kim Seok Lee Chang-Ki Min Seok-Goo Cho Jong Wook Lee Source Type: research

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis
This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute.RESULTS: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI], 1.23-7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI, 1.58-5.53; p
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Yosuke Okada Masahiro Teramoto Noriaki Tachi Toshikuni Kawamura Toshikatsu Horiuchi Shoichiro Kato Takaaki Maekawa Yukiko Osawa Shinichi Kobayashi Fumihiko Kimura Source Type: research

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response
CONCLUSIONS: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy.PMID:35016175 | DOI:10.1159/000521912 (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Daehun Kwag Jae-Ho Yoon Gi June Min Sung-Soo Park Silvia Park Sung Eun Lee Byung-Sin Cho Ki-Seong Eom Yoo-Jin Kim Hee-Je Kim Seok Lee Chang-Ki Min Seok-Goo Cho Jong Wook Lee Source Type: research

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis
This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute.RESULTS: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI], 1.23-7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI, 1.58-5.53; p
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Yosuke Okada Masahiro Teramoto Noriaki Tachi Toshikuni Kawamura Toshikatsu Horiuchi Shoichiro Kato Takaaki Maekawa Yukiko Osawa Shinichi Kobayashi Fumihiko Kimura Source Type: research

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response
CONCLUSIONS: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy.PMID:35016175 | DOI:10.1159/000521912 (Source: Acta Haematologica)
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Daehun Kwag Jae-Ho Yoon Gi June Min Sung-Soo Park Silvia Park Sung Eun Lee Byung-Sin Cho Ki-Seong Eom Yoo-Jin Kim Hee-Je Kim Seok Lee Chang-Ki Min Seok-Goo Cho Jong Wook Lee Source Type: research

The Prognostic Impact of MYC Gene-Related Abnormalities on Multiple Myeloma Outcome through Fluorescence in situ Hybridization Analysis
This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence in situ hybridization analysis in our institute.RESULTS: MYC GAs were associated with poor overall survival (hazard ratio [HR], 3.08; 95% confidence interval [CI], 1.23-7.73; p = 0.017), progression-free survival (PFS) (HR, 2.96; 95% CI, 1.58-5.53; p
Source: Acta Haematologica - January 11, 2022 Category: Hematology Authors: Yosuke Okada Masahiro Teramoto Noriaki Tachi Toshikuni Kawamura Toshikatsu Horiuchi Shoichiro Kato Takaaki Maekawa Yukiko Osawa Shinichi Kobayashi Fumihiko Kimura Source Type: research

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
In this study, 2 independent patient care data sources were queried (Cardinal Health Oncology Provider Extended Network [OPEN] and HealthCore Integrated Research Environment [HIRE®]), and a retrospective review of medical charts was conducted. Patients aged ≥18 years with a diagnosis of myelofibrosis (primary or secondary), use of ruxolitinib for myelofibrosis, and documented physician-directed ruxolitinib interruption were included. Among 26 included patients, pre-interruption median (interquartile range [IQR]) ruxolitinib treatment duration was 123 (57-391, OPEN) and 110 (37-148, HIRE) days. Half the patients inte...
Source: Acta Haematologica - January 10, 2022 Category: Hematology Authors: Aaron T Gerds Jingbo Yu Robyn M Scherber Dilan Paranagama Jonathan K Kish Jay Visaria Mukul Singhal Srdan Verstovsek Naveen Pemmaraju Source Type: research

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
In this study, 2 independent patient care data sources were queried (Cardinal Health Oncology Provider Extended Network [OPEN] and HealthCore Integrated Research Environment [HIRE ®]), and a retrospective review of medical charts was conducted. Patients aged ≥18 years with a diagnosis of myelofibrosis (primary or secondary), use of ruxolitinib for myelofibrosis, and documented physician-directed ruxolitinib interruption were included. Among 26 included patients, pre-interr uption median (interquartile range [IQR]) ruxolitinib treatment duration was 123 (57–391, OPEN) and 110 (37–148, HIRE) days. Half the...
Source: Acta Haematologica - January 10, 2022 Category: Hematology Source Type: research

Erratum
Acta Haematol (Source: Acta Haematologica)
Source: Acta Haematologica - January 4, 2022 Category: Hematology Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
Conclusion: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice. (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Romiplostim for Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany
CONCLUSION: Romiplostim was effective and well tolerated in patients with newly diagnosed, persistent, or chronic ITP in routine clinical practice.PMID:34959233 | DOI:10.1159/000521689 (Source: Acta Haematologica)
Source: Acta Haematologica - December 27, 2021 Category: Hematology Authors: Marcel Reiser Klaus M Josten Hermann Dietzfelbinger Anouchka Seesaghur Markus Schill Jane Hippenmeyer Manfred Welslau Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.PMID:34913873 | DOI:10.1159/000520438 (Source: Acta Haematologica)
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Amit R Mehta Aron Kefela Charina Toste Donald Sweet Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
Acta Haematol. 2021 Dec 14. doi: 10.1159/000521445. Online ahead of print.ABSTRACTSTAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/β-catenin pathway. The prognostic analysis exhibited that...
Source: Acta Haematologica - December 16, 2021 Category: Hematology Authors: Shuxin Xiao Chuanbo Fan Jinlong Ma Hongwei Xue Liqin Xu Source Type: research

Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
We present a case series of 5 patients with ITP who had significant CV histories; each had at least 2 thrombotic risk factors. After unsuccessful management of ITP with other treatments, fostamatinib was initiated, was observed to be tolerable, and provided a durable platelet response without associated thromboembolic events. Fostamatinib may be the treatment of choice for patients with ITP in whom use of prothrombotic treatments should be avoided and/or continued use of antiplatelet or anticoagulant medication is needed.Acta Haematol (Source: Acta Haematologica)
Source: Acta Haematologica - December 14, 2021 Category: Hematology Source Type: research

STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma
STAT3 is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. We studied here whether STAT3 contributes to CCL4 transcription elevation in DLBCL. Our established protein-protein interactions (PPI) network revealed the overexpression of STAT3 and CCL4 in DLBCL. Mechanistically, STAT3 activated CCL4 transcription to induce the Wnt/ β-catenin pathway. The prognostic analysis exhibited that the overall survival of patients with high STAT3 and CCL4 were poorer than those...
Source: Acta Haematologica - December 14, 2021 Category: Hematology Source Type: research

Using Circ-ANAPC7 as a Novel Type of Biomarker in the Monitoring of Acute Myeloid Leukemia
Acta Haematol. 2021 Dec 8:1-7. doi: 10.1159/000520446. Online ahead of print.ABSTRACTINTRODUCTION: Circular RNAs (circRNAs) are a novel class of RNAs which occupy gene expression at the transcriptional or post-transcriptional level, involve in many physiological processes, and participate in many diseases, especially in cancer. Our previous study showed 1 altered circRNA named circ-anaphase promoting complex subunit 7 (ANAPC7) that was upregulated in acute myeloid leukemia (AML). To further clear the expression and clinical significance of circ-ANAPC7, we enlarged the sample size and illuminated the diagnostic and monitori...
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Ying Shen Yachun Jia Ru Zhang Hongli Chen Yuandong Feng Fangmei Li Ting Wang Ju Bai Aili He Yun Yang Source Type: research

Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics
CONCLUSIONS: 1. Weight, blood types, and bleeding types of adult SHA patients could affect FVIII half-life. As body mass index increased, FVIII half-life were significantly prolonged. The FVIII half-life of patients with type O blood were significantly shorter than those with other blood types, and the FVIII half-life of knee joint bleeding were conspicuously shorter than those of elbow joint bleeding. 2. Individualized preventive treatment could markedly reduce bleeding times. For patients with a long half-life period, the total annual FⅧ dosage could be reduced to achieve bleeding prevention and economic benefit.PMID:3...
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Youqun Wang Qiao Yang Liangda Zheng Xianting Wang Wenhua Jiang Lijun Lu Lixia Yan Miaomiao Zhang Lili Chen Source Type: research

Reproductive Failure and Thrombophilia: Not Enough Evidence for a Tight Bond
CONCLUSIONS: Incidence of thrombophilia is increased among women with RF, but the severity or type of thrombophilia is not related to pregnancy outcome.PMID:34879375 | DOI:10.1159/000520439 (Source: Acta Haematologica)
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Maria Stamou Stergios Intzes Marianthi Symeonidou Ioanna Bazntiara Zoe Bezirgiannidou Aikaterini Pentidou Christina Misidou Konstantinos Liapis Dimitrios Margaritis Ioannis Kotsianidis Emmanouil Spanoudakis Source Type: research

Two Sides of a Coin: Case Report of Unilateral Synangiosis and Contralateral Stroke Highlighting Consequences of Disease Progression and Efficacy of Revascularization in Sickle Cell Disease Associated Moyamoya Syndrome
We describe a challenging case where a patient with sickle cell disease undergoing standard of care management as prescribed by the Stroke Prevention Trial in Sickle Cell Anemia (STOP) and revascularization with pial synangiosis subsequently developed rapidly progressive disease in other cerebral vessels and suffered ischemic hemispheric stroke. This case demonstrates the success of management in accordance with American Heart Association (AHA) and American Stroke Association (ASA) guidelines, but also demonstrates critical areas where we lack understanding of disease progression.PMID:34879377 | DOI:10.1159/000521361 (Sour...
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Anna L Slingerland Madeline B Karsten Edward R Smith Amy E Sobota Alfred P See Source Type: research

Using Circ-ANAPC7 as a Novel Type of Biomarker in the Monitoring of Acute Myeloid Leukemia
Acta Haematol. 2021 Dec 8:1-7. doi: 10.1159/000520446. Online ahead of print.ABSTRACTINTRODUCTION: Circular RNAs (circRNAs) are a novel class of RNAs which occupy gene expression at the transcriptional or post-transcriptional level, involve in many physiological processes, and participate in many diseases, especially in cancer. Our previous study showed 1 altered circRNA named circ-anaphase promoting complex subunit 7 (ANAPC7) that was upregulated in acute myeloid leukemia (AML). To further clear the expression and clinical significance of circ-ANAPC7, we enlarged the sample size and illuminated the diagnostic and monitori...
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Ying Shen Yachun Jia Ru Zhang Hongli Chen Yuandong Feng Fangmei Li Ting Wang Ju Bai Aili He Yun Yang Source Type: research

Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics
CONCLUSIONS: 1. Weight, blood types, and bleeding types of adult SHA patients could affect FVIII half-life. As body mass index increased, FVIII half-life were significantly prolonged. The FVIII half-life of patients with type O blood were significantly shorter than those with other blood types, and the FVIII half-life of knee joint bleeding were conspicuously shorter than those of elbow joint bleeding. 2. Individualized preventive treatment could markedly reduce bleeding times. For patients with a long half-life period, the total annual FⅧ dosage could be reduced to achieve bleeding prevention and economic benefit.PMID:3...
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Youqun Wang Qiao Yang Liangda Zheng Xianting Wang Wenhua Jiang Lijun Lu Lixia Yan Miaomiao Zhang Lili Chen Source Type: research

Reproductive Failure and Thrombophilia: Not Enough Evidence for a Tight Bond
CONCLUSIONS: Incidence of thrombophilia is increased among women with RF, but the severity or type of thrombophilia is not related to pregnancy outcome.PMID:34879375 | DOI:10.1159/000520439 (Source: Acta Haematologica)
Source: Acta Haematologica - December 8, 2021 Category: Hematology Authors: Maria Stamou Stergios Intzes Marianthi Symeonidou Ioanna Bazntiara Zoe Bezirgiannidou Aikaterini Pentidou Christina Misidou Konstantinos Liapis Dimitrios Margaritis Ioannis Kotsianidis Emmanouil Spanoudakis Source Type: research